Williams & Novak’s Taysha Gene Therapies TSHA Stock Holding History

Williams & Novak’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Hold	45,000	–	–	0.2%	99
2026 Q1	$194K	Hold	45,000	–	–	0.15%	108
2025 Q4	$248K	Hold	45,000	–	–	0.19%	96
2025 Q3	$147K	Hold	45,000	–	–	0.11%	115
2025 Q2	$104K	Hold	45,000	–	–	0.09%	112
2025 Q1	$56.9K	Hold	45,000	–	–	0.06%	114
2024 Q4	$77.8K	Hold	45,000	–	–	0.08%	119
2024 Q3	$90.5K	Hold	45,000	–	–	0.08%	118
2024 Q2	$101K	Hold	45,000	–	–	0.09%	114
2024 Q1	$79.7K	Hold	45,000	–	–	0.09%	85
2023 Q4	$79.7K	Buy	+45,000	New	+$89.7K	0.09%	85

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Williams & Novak's TSHA Position: Q2 2026 in Review

Williams & Novak held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 45,000 shares worth $306K. The position accounts for 0.2% of the portfolio, ranked #99.

Williams & Novak first reported a position in TSHA in Q4 2023 and has held it in 11 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Williams & Novak held 45,000 shares of Taysha Gene Therapies worth $306K as of Q2 2026.
Williams & Novak left its Taysha Gene Therapies share count unchanged in Q2 2026.
Taysha Gene Therapies made up 0.2% of Williams & Novak's portfolio in Q2 2026, its #99 holding.
Williams & Novak first reported a position in Taysha Gene Therapies in Q4 2023 and has held it in 11 quarters since.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Williams & Novak's 13F filing for Q2 2026, filed 8 Jul 2026.